These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31922030)

  • 1. The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care.
    Patorno E; Najafzadeh M; Pawar A; Franklin JM; Déruaz-Luyet A; Brodovicz KG; Santiago Ortiz AJ; Bessette LG; Kulldorff M; Schneeweiss S
    Endocrinol Diabetes Metab; 2020 Jan; 3(1):e00103. PubMed ID: 31922030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
    Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
    Vistisen D; Carstensen B; Elisabetta P; Lanzinger S; Tan EC; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Núñez J; Ha KH; Halvorsen S; Langslet G; Karasik A; Nyström T; Niskanen L; Guleria S; Klement R; Carrasco M; Foersch J; Shay C; Koeneman L; Hoti F; Farsani SF; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; ;
    Cardiovasc Diabetol; 2023 Aug; 22(1):233. PubMed ID: 37653496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.
    Seino Y; Kim DJ; Yabe D; Tan EC; Chung WJ; Ha KH; Nangaku M; Node K; Klement R; Yasui A; Lei WY; Lee S; Kyaw MH; Deruaz-Luyet A; Brodovicz KG; H-H Sheu W;
    Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00183. PubMed ID: 33532619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Patorno E; Pawar A; Wexler DJ; Glynn RJ; Bessette LG; Paik JM; Najafzadeh M; Brodovicz KG; Déruaz-Luyet A; Schneeweiss S
    Diabetes Obes Metab; 2022 Mar; 24(3):442-454. PubMed ID: 34729891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase-4 inhibitors: Real world evidence from the Nordic EMPRISE study.
    Nyström T; Toresson Grip E; Gunnarsson J; Casajust P; Karlsdotter K; Skogsberg J; Ustyugova A;
    Diabetes Obes Metab; 2023 Jan; 25(1):261-271. PubMed ID: 36097728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
    Cardiovasc Diabetol; 2024 Feb; 23(1):57. PubMed ID: 38331813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
    Karasik A; Lanzinger S; Chia-Hui Tan E; Yabe D; Kim DJ; Sheu WH; Melzer-Cohen C; Holl RW; Ha KH; Khunti K; Zaccardi F; Subramanian A; Nirantharakumar K; Nyström T; Niskanen L; Linnemann Jensen M; Hoti F; Klement R; Déruaz-Luyet A; Kyaw MH; Koeneman L; Vistisen D; Carstensen B; Halvorsen S; Langslet G; Fazeli Farsani S; Patorno E; Núñez J;
    Diabetes Metab; 2023 Mar; 49(2):101418. PubMed ID: 36608816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.
    Kim DJ; Sheu WH; Chung WJ; Yabe D; Ha KH; Nangaku M; Tan EC; Node K; Yasui A; Lei W; Lee S; Saarelainen L; Deruaz-Luyet A; Kyaw MH; Seino Y;
    J Diabetes Investig; 2023 Mar; 14(3):417-428. PubMed ID: 36716212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
    J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data.
    Mishriky BM; Cummings DM; Fu Y; Halladay JR; Jones S; Boan AD; Jones S; Patil SP; Powell JR; Adams A; Irish W
    Diabetes Obes Metab; 2024 May; 26(5):1830-1836. PubMed ID: 38361455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial.
    Verma S; Leiter LA; Zinman B; Sharma A; Mattheus M; Fitchett D; George J; Ofstad AP; Kosiborod MN; Wanner C; Inzucchi SE
    ESC Heart Fail; 2021 Aug; 8(4):2603-2607. PubMed ID: 34132492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
    Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
    BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Verma S; Sharma A; Zinman B; Ofstad AP; Fitchett D; Brueckmann M; Wanner C; Zwiener I; George JT; Inzucchi SE; Butler J; Mazer CD
    Diabetes Obes Metab; 2020 Jul; 22(7):1141-1150. PubMed ID: 32227432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
    Reifsnider OS; Kansal AR; Wanner C; Pfarr E; Koitka-Weber A; Brand SB; Stargardter M; Wang C; Kuti E; Ustyugova A
    Am J Kidney Dis; 2022 Jun; 79(6):796-806. PubMed ID: 34752913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
    Sharma A; Ofstad AP; Ahmad T; Zinman B; Zwiener I; Fitchett D; Wanner C; George JT; Hantel S; Desai N; Mentz RJ
    JACC Heart Fail; 2021 Aug; 9(8):568-577. PubMed ID: 34325887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial.
    Fitchett D; Inzucchi SE; Zinman B; Wanner C; Schumacher M; Schmoor C; Ohneberg K; Ofstad AP; Salsali A; George JT; Hantel S; Bluhmki E; Lachin JM; Zannad F
    ESC Heart Fail; 2021 Dec; 8(6):4517-4527. PubMed ID: 34605192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.